Msa2 affinity-enhanced biotin-binding chimeric antigen receptor (car)
AssigneeUniversity of Pittsburgh—Of the Commonwealth System of Higher Education
InventorJason Lohmueller
Life of this patent
Estimating the term…
Abstract
A chimeric antigen receptor is disclosed that includes: (a) an extracellular high affinity streptavidin;(b) a hinge domain from CD8; (c) a CD28 transmembrane domain; (d) an intracellular 4-1BB and/or CD28 signaling domain; and (e) an intracellular CD3 zeta signaling domain, wherein (a)-(e) are in N-terminal to C-terminal order. Nucleic acids encoding this chimeric antigen receptor, and T and natural killer (NK) cells transformed with this chimeric antigen receptor are also disclosed. The use of this chimeric antigen receptor for the treatment of tumors is also disclosed.
Claims28
A chimeric antigen receptor comprising:
- (a) an extracellular high affinity streptavidin;
- (b) a hinge domain from CD8;
- (c) a CD28 transmembrane domain;
- (d) an intracellular 4-1BB and/or CD28 signaling domain;
- and
- (e) an intracellular CD3 zeta signaling domain, wherein (a)-(e) are in N-terminal to C-terminal order.
The isolated nucleic acid molecule of claim 14, comprising the nucleic acid sequence of SEQ ID NO:
- 19.
The method of claim 26 or claim 27, wherein
- a) the pharmaceutical composition comprises the CD3+ T cells, wherein the CD3+CD4+ T cells and/or CD3+CD8+ T cells;
- and/or
- b) the tumor associated antigen is MUC-1, CD19 or CD20.
Dependencies are inferred from the claim text.